Complete Genomics plans $30 million at market issuance sales agreement

Agent MLV helps company raise proceeds for general corporate purposes

By Devika Patel

Knoxville, Tenn., March 12 - Complete Genomics, Inc. negotiated a $30 million at-market issuance sales agreement to sell its common stock, according to a prospectus supplement and 8-K filed Monday with the Securities and Exchange Commission.

MLV & Co. LLC is the agent.

Proceeds will be used for general corporate purposes.

Mountain View, Calif.-based Complete Genomics makes a DNA sequencing platform for human genome sequencing and analysis.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.